September 17, 2026

@michaelokun

What resonated with me from today’s DBS Think Tank XIV Industry Blitz was the remarkable pace of innovation and, even more importantly, the growing power of academic-industry partnership to move the field forward. Andrew Haddock from Boston Scientific, Ben Isaacson from Medtronic, David Greene from NeuroPace and Lyndahl Himes/Yagna Pathak from Abbott each provided a glimpse into where neuromodulation is headed, from smarter devices and sensing to more personalized and adaptive approaches. Industry continues to blaze new paths, but the magic happens when engineers and innovators work shoulder-to-shoulder with academicians and clinicians to ask the difficult questions, perform the rigorous studies and generate the evidence necessary to push the horizon. The technology is exciting, but technology alone is not the destination. The destination is impact: better therapies, better outcomes and better lives for the people we serve.